Shai Shimony

Oncology

450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology

Published: June 25, 2026

Real-world outcomes of venetoclax plus hypomethylating agents in BPDCN across treatment lines.

Real-world outcomes of venetoclax plus hypomethylating agents in BPDCN across treatment lines.

Journal: Haematologica

Published: June 03, 2026

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

Journal: The American journal of surgical pathology

Published: April 20, 2026

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal: Blood

Published: March 03, 2026

Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.

Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.

Journal: Leukemia & lymphoma

Published: January 26, 2026

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Journal: Blood advances

Published: December 11, 2025

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

Journal: Blood advances

Published: December 11, 2025

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Journal: Haematologica

Published: November 10, 2025

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

Journal: JACC. CardioOncology

Published: October 14, 2025

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Journal: Blood neoplasia

Published: September 18, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances

Published: September 16, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026